C. R. Bradley
Annexon Biosciences (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Glass properties and applications, Nuclear materials and radiation effects, Cancer Treatment and Pharmacology, DNA Repair Mechanisms
Most-Cited Works
- → Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer(2011)808 cited
- → Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial(2009)243 cited
- → Colloid Formation During Waste Form Reaction: Implications for Nuclear Waste Disposal(1992)143 cited
- Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.(2011)
- → First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors(2008)61 cited
- → A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors(2008)51 cited
- → Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).(2009)41 cited
- → High-level waste borosilicate glass: A compendium of corrosion characteristics. Volume 3(1994)34 cited